A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways
Chemistry – A European Journal · 2024
DOI: 10.1002/chem.202400080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Tommaso Garfagnini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat Ram, 9190401, Jerusalem, Israel. Hauptthemen laut MEDLINE: Peptides, Protein Aggregates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FP7 People: Marie-Curie Actions.
Abstract (Originalsprache)
Protein aggregation correlates with many human diseases. Protein aggregates differ in structure and shape. Strategies to develop effective aggregation inhibitors that reach the clinic failed so far. Here, we developed a family of peptides targeting early aggregation stages for both amorphous and fibrillar aggregates of proteins unrelated in sequence and structure. They act on dynamic precursors before mechanistic differentiation takes place. Using peptide arrays, we first identified peptides inhibiting the amorphous aggregation of a molten globular, aggregation‐prone mutant of the Axin tumor suppressor. Optimization revealed that the peptides activity did not depend on their sequences but rather on their molecular determinants: a composition of 20–30 % flexible, 30–40 % aliphatic and 20–30 % aromatic residues, a hydrophobicity/hydrophilicity ratio close to 1, and an even distribution of residues of different nature throughout the sequence. The peptides also suppressed fibrillation of Tau, a disordered protein that forms amyloids in Alzheimer's disease, and slowed down that of Huntingtin Exon1, an amyloidogenic protein in Huntington's disease, both entirely unrelated to Axin. Our compounds thus target early stages of different aggregation mechanisms, inhibiting both amorphous and amyloid aggregation. Such cross‐mechanistic, multi‐targeting aggregation inhibitors may be lead compounds for developing drug candidates against various protein aggregation diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat Ram, 9190401, Jerusalem, Israel.
- Cellular Protein Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584, Utrecht CH, The Netherlands.
- Science for Life, Utrecht University, Padualaan 8, 3584, Utrecht CH, The Netherlands.
- Max Perutz Labs, Vienna BioCenter (VBC), University of Vienna, Vienna, Austria.
- Oncode Institute, Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, 3584, Utrecht CH, The Netherlands.
ORCID-Profile: Assaf Friedler
Förderung
- FP7 People: Marie-Curie Actions
Zitieren
APA
Garfagnini, T., Ferrari, L., Koopman, M. B., Dekker, F. A., Halters, S., Van Kappel, E., Mayer, G., Bressler, S., Maurice, M. M., Rüdiger, S. G. D., & Friedler, A. (2024). A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways. Chemistry – A European Journal. https://doi.org/10.1002/chem.202400080
Vancouver
Garfagnini T, Ferrari L, Koopman MB, Dekker FA, Halters S, Van Kappel E, et al. A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways. Chemistry – A European Journal. 2024. doi:10.1002/chem.202400080
BibTeX
@article{Garfagnini2024,
author = {Garfagnini, Tommaso and Ferrari, Luca and Koopman, Margreet B and Dekker, Françoise A and Halters, Sem and Van Kappel, Eline and Mayer, Guy and Bressler, Shachar and Maurice, Madelon M and Rüdiger, Stefan G D and Friedler, Assaf},
title = {A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways},
journal = {Chemistry – A European Journal},
year = {2024},
doi = {10.1002/chem.202400080}
}
EUVIMED